Swapping out standard locking fluids for 4% tetrasodium EDTA in ICU central lines slashed complication rates by 32%, according to a multicenter randomized trial published in JAMA. The biggest win was fewer catheter occlusions requiring the clot-busting drug alteplase. The findings could ease nursing burden — though cost-effectiveness questions remain.
ICU patients with central venous access devices (CVADs) saw significantly fewer complications when their line-locking fluid was switched from standard saline or citrate to 4% tetrasodium EDTA (t-EDTA), according to results from the CLiCK trial presented at the American Thoracic Society International Conference and simultaneously published in JAMA. The pragmatic, triple-blind, cluster-randomized crossover trial enrolled 1,468 adults across six Canadian hospitals — three academic, three community — making the findings broadly generalizable.
The composite complication rate dropped 32% with t-EDTA versus control (13.1 vs. 19.9 events per 1,000 catheter-days). The main driver was a 34% reduction in catheter occlusions requiring alteplase — a meaningful outcome given the nursing time and care interruptions these events cause. The benefit was especially pronounced in patients with peripherally inserted central catheters and those with seven or more days of CVAD use. No adverse events, including calcium-related concerns, were observed.
Key Takeaways:
Why it matters: Central line complications are a major source of morbidity and nursing burden in the ICU. A locking fluid that meaningfully reduces occlusions could improve patient outcomes and ease clinical workflow — though broader adoption will likely hinge on further cost-effectiveness data, particularly for U.S. settings.
